Serum XXXX Levels and @entity1 Outcomes in an Ambulatory Clinic-Based @entity740 Cohort.

@entity1 @entity8 @entity712 @entity4024 @entity1009 @entity1372 @entity740 @entity177 @entity3489 @entity454
BACKGROUND: @entity740 ( @entity740 ) @entity1 are prone to both hypo- and @entity3489 . Little has been published on the epidemiology of hypo- and @entity3489 in ambulatory @entity1 with non-dialysis @entity740 . METHODS: Data collected in two contemporaneous @entity740 cohort studies, the @entity8 ( @entity8 )- @entity740 study (n = 834) and the Study of Treatment of @entity177 : Data and Evaluation (STRIDE) (n = 1,348) were combined and analyzed to study the association between serum @entity1372 ( @entity4024 ) and clinical outcomes. RESULTS: Baseline estimated glomerular filtration rate (eGFR) and @entity4024 were 26    11 ml/ @entity1009 .73 m(2) and 140.2    3.4 mEq/l, respectively. The prevalence of @entity4024  <=135 mEq/l and >= 144 mEq/l was 6 and 16%, respectively. Higher baseline @entity4024 was significantly associated with male sex, older age, systolic blood pressure, BMI, serum albumin, presence of @entity712 , and lower eGFR. The risk of @entity454 ( @entity454 ) was marginally significantly higher among @entity1 with @entity4024  <=135 mEq/l, compared with 140< @entity4024 <144 mEq/l (referent), in time-dependent models (adjusted hazard ratio, HR = 1.52, p = 0.06). Mortality risk was significantly greater at 135< @entity4024  <=140 mEq/l (adjusted HR = 1.68, p = 0.02) and @entity4024 >= 144 mEq/l (adjusted HR = 2.01, p = 0.01). CONCLUSION: @entity740 @entity1 with @entity4024  <=135 mEq/l were at a higher risk for progression to @entity454 , whereas both lower and higher @entity4024 levels were associated with a higher risk of mortality. While caring for @entity740 @entity1 , greater attention to serum @entity1372 levels by clinicians is warranted and could potentially help improve @entity1 outcomes.    2015 S. Karger AG, Basel.
